A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

Summary

X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

Timeline

Start

2024-12-20

Primary completion

2026-08

Completion

2026-10

Drugs

Indications